Lisa G. Ensign

911 total citations
15 papers, 669 citations indexed

About

Lisa G. Ensign is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Infectious Diseases. According to data from OpenAlex, Lisa G. Ensign has authored 15 papers receiving a total of 669 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Pulmonary and Respiratory Medicine, 4 papers in Oncology and 3 papers in Infectious Diseases. Recurrent topics in Lisa G. Ensign's work include Antifungal resistance and susceptibility (3 papers), Renal and related cancers (3 papers) and Sarcoma Diagnosis and Treatment (3 papers). Lisa G. Ensign is often cited by papers focused on Antifungal resistance and susceptibility (3 papers), Renal and related cancers (3 papers) and Sarcoma Diagnosis and Treatment (3 papers). Lisa G. Ensign collaborates with scholars based in United States, France and Netherlands. Lisa G. Ensign's co-authors include Harold M. Maurer, Edmund A. Gehan, Moody D. Wharam, Peter F. Thall, Adel K. El‐Naggar, R. Beverly Raney, William A. Newton, Keith M. Heaton, Merrick I. Ross and Melvin Tefft and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and Annals of Surgery.

In The Last Decade

Lisa G. Ensign

15 papers receiving 648 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lisa G. Ensign United States	12	235	188	138	114	102	15	669
J. W. Andersen United States	10	145 0.6×	290 1.5×	100 0.7×	132 1.2×	50 0.5×	13	960
Philippe Moulin Belgium	19	135 0.6×	131 0.7×	27 0.2×	71 0.6×	75 0.7×	46	935
Lucy Rowell United Kingdom	16	118 0.5×	274 1.5×	87 0.6×	58 0.5×	70 0.7×	31	1.2k
Tracy Burgess United States	14	181 0.8×	72 0.4×	266 1.9×	65 0.6×	444 4.4×	19	1.1k
Timothée Olivier Switzerland	15	341 1.5×	463 2.5×	42 0.3×	99 0.9×	64 0.6×	83	873
A Nagler Israel	18	92 0.4×	352 1.9×	113 0.8×	54 0.5×	60 0.6×	42	1.4k
S W McCarthy Australia	12	208 0.9×	538 2.9×	227 1.6×	56 0.5×	157 1.5×	21	874
Sedigheh Keyhani‐Rofagha United States	16	81 0.3×	151 0.8×	139 1.0×	132 1.2×	195 1.9×	30	583
Joseph W.Y. Lau Hong Kong	13	118 0.5×	189 1.0×	178 1.3×	66 0.6×	306 3.0×	31	860
Peter R. Graze United States	10	183 0.8×	222 1.2×	111 0.8×	118 1.0×	57 0.6×	15	726

Countries citing papers authored by Lisa G. Ensign

Since Specialization

Citations

This map shows the geographic impact of Lisa G. Ensign's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lisa G. Ensign with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lisa G. Ensign more than expected).

Fields of papers citing papers by Lisa G. Ensign

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lisa G. Ensign. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lisa G. Ensign. The network helps show where Lisa G. Ensign may publish in the future.

Co-authorship network of co-authors of Lisa G. Ensign

This figure shows the co-authorship network connecting the top 25 collaborators of Lisa G. Ensign. A scholar is included among the top collaborators of Lisa G. Ensign based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lisa G. Ensign. Lisa G. Ensign is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Blum, Kevin M., et al.. (2021). Oncology trial enrollment trends following the first wave of the COVID-19 pandemic.. Journal of Clinical Oncology. 39(15_suppl). 1565–1565. 1 indexed citations

Ensign, Lisa G. & Kevin Bretonnel Cohen. (2017). A Primer to the Structure, Content and Linkage of the FDA’s Manufacturer and User Facility Device Experience (MAUDE) Files. eGEMs (Generating Evidence & Methods to improve patient outcomes). 5(1). 12–12. 26 indexed citations

Ensign, Lisa G., et al.. (2017). A Primer to the Structure, Content and Linkage of the FDA’s Manufacturer and User Facility Device Experience (MAUDE) Files. eGEMs (Generating Evidence & Methods to improve patient outcomes). 5(1). 12–12. 2 indexed citations

Kay, G. Neal, Jeffrey Brinker, David T. Kawanishi, et al.. (1999). Risks of Spontaneous Injury and Extraction of an Active Fixation Pacemaker Lead. Circulation. 100(23). 2344–2352. 68 indexed citations

Wharam, Moody D., John Hanfelt, Mariella C. Tefft, et al.. (1997). Radiation therapy for rhabdomyosarcoma: Local failure risk for Clinical Group III patients on Intergroup Rhabdomyosarcoma Study II. International Journal of Radiation Oncology*Biology*Physics. 38(4). 797–804. 52 indexed citations

Anaissie, E., Victor L. Paetznick, Lisa G. Ensign, et al.. (1996). Microdilution antifungal susceptibility testing of Candida albicans and Cryptococcus neoformans with and without agitation: an eight-center collaborative study. Antimicrobial Agents and Chemotherapy. 40(10). 2387–2391. 25 indexed citations

Heaton, Keith M., et al.. (1994). Surgical Management and Prognostic Factors in Patients with Subungual Melanoma. Annals of Surgery. 219(2). 197–204. 88 indexed citations

Ensign, Lisa G., et al.. (1994). An optimal three‐stage design for phase II clinical trials. Statistics in Medicine. 13(17). 1727–1736. 89 indexed citations

El‐Naggar, Adel K., et al.. (1994). Interphase cytogenetics in paraffin-embedded sections from renal cortical neoplasms. Cancer Genetics and Cytogenetics. 73(2). 134–141. 17 indexed citations

10.

Heyn, Ruth, Lisa G. Ensign, Sarah S. Donaldson, et al.. (1994). Acute myeloid leukemia in patients treated for rhabdomyosarcoma with cyclophosphamide and low‐dose etoposide on intergroup rhabdomyosarcoma study III: An interim report. Medical and Pediatric Oncology. 23(2). 99–106. 55 indexed citations

11.

Raney, Beverly, Lisa G. Ensign, William A. Newton, et al.. (1994). Renal toxicity of ifosfamide in pilot regimens of the intergroup rhabdomyosarcoma study for patients with gross residual tumor.. PubMed. 16(4). 286–95. 43 indexed citations

12.

Anaissie, E., et al.. (1993). Two-site comparison of broth microdilution and semisolid agar dilution methods for susceptibility testing of Cryptococcus neoformans in three media. Journal of Clinical Microbiology. 31(5). 1370–1372. 8 indexed citations

13.

El-Naggar, Adel K., Jae Y. Ro, & Lisa G. Ensign. (1993). Papillary renal cell carcinoma: Clinical implication of DNA content analysis. Human Pathology. 24(3). 316–321. 26 indexed citations

14.

Heyn, R, William A. Newton, A H Ragab, et al.. (1993). Second malignant neoplasms in children treated for rhabdomyosarcoma. Intergroup Rhabdomyosarcoma Study Committee.. Journal of Clinical Oncology. 11(2). 262–270. 136 indexed citations

15.

Shawar, Ribhi M., et al.. (1992). Collaborative investigation of broth microdilution and semisolid agar dilution for in vitro susceptibility testing of Candida albicans. Journal of Clinical Microbiology. 30(8). 1976–1981. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact